Recent Stories
Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: RobotsBlack October Wasn't an Attack Wave. It Was a Warning.Extreme Ownership Means Ultimate Achievement – NASA Culture Shift
← Back to the board
Money

HHS ASPR awarded Basilea Pharmaceutica contract 75A50123C00050 for about $45.2 million to develop new antibiotics against drug-resistant gram-negative bacteria.

Why it’s here: A $45M ASPR award for development of novel antibiotics against drug-resistant bacteria is federally funded biotechnology tied to biosecurity and pandemic preparedness, which falls within the biotechnology scope.

Trace across the board

Item

Connected

12 links

About

  • Department of Health and Human Services

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

HHS ASPR awarded Basilea Pharmaceutica contract 75A50123C00050 for about $45.2 million to develop new antibiotics against drug-resistant gram-negative bacteria. — The Wave